Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

NEWRON PHARMACEUTICALS SPA (NWRN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
10.02(c) 9.96(c) 10.3(c) 10.26(c) 10.32(c) Last
27 991 18 156 103 607 53 341 26 547 Volume
-0.79% -0.60% +3.41% -0.39% +0.58% Change
More quotes
Financials (€)
Sales 2017 14,5 M
EBIT 2017 -11,8 M
Net income 2017 -12,1 M
Finance 2017 57,2 M
Yield 2017 -
Sales 2018 10,2 M
EBIT 2018 -23,0 M
Net income 2018 -25,1 M
Finance 2018 36,3 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 7,07x
EV / Sales2018 12,1x
Capitalization 160 M
More Financials
Company
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain.The focus of its treatments includes patients with Parkinson's disease, Rett Syndrome, Amyotrophic Lateral Sclerosis,... 
More about the company
Surperformance© ratings of Newron Pharmaceuticals SpA
Trading Rating : Investor Rating :
More Ratings
Latest news on NEWRON PHARMACEUTICALS SPA
02/13NEWRON PHARMACEUTICALS : Supports Global Rare Disease Day® 2018 and Rett Syndrom..
BU
02/13Newron Supports Global Rare Disease Day® 2018 and Rett Syndrome Studies
TE
02/13NEWRON PHARMACEUTICALS : Supports Global Rare Disease Day® 2018 and Rett Syndrom..
AQ
02/08NEWRON PHARMACEUTICALS S.P.A. : Announces Change in the Board of Directors
BU
02/08Change in the Board of Directors
TE
02/08NEWRON PHARMACEUTICALS : Change in the Board of Directors
AQ
02/06NEWRON PHARMACEUTICALS : to Present at the 20th Annual BIO CEO & Investor Confer..
BU
02/01NEWRON PHARMACEUTICALS : Primary endpoint met in phase III clinical study of inv..
PU
2017NEWRON PHARMACEUTICALS : making significant progress including US approval of Xa..
AQ
2017NEWRON PHARMACEUTICALS : Provides End of Year Corporate Update
BU
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/08Newron Pharmaceuticals S.p.A. Announces Change in the Board of Directors: MIL.. 
02/08Newron Pharmaceuticals S.p.A. Announces Change in the Board of Directors  
02/06Newron Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor C.. 
02/06Newron Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor C.. 
02/06Newron Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor C.. 
More tweets
Qtime:23
News from SeekingAlpha
2017Newron Pharmaceuticals SPA reports 1H results 
2017Newron Pharmaceuticals SPA reports FY results 
2016FDA accepts for review Newron's resubmitted NDA for Xadago; action date March.. 
2016Newron Pharmaceuticals SPA reports 1H results 
2015TOP 2 TRADE ALERT IDEAS SEPTEMBER 30 : Esperion Sell-Off, Clovis Milestone, Wind.. 
Chart NEWRON PHARMACEUTICALS SPA
Duration : Period :
Newron Pharmaceuticals SpA Technical Analysis Chart | NWRN | IT0004147952 | 4-Traders
Technical analysis trends NEWRON PHARMACEUTICALS SPA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 28,3 €
Spread / Average Target 216%
EPS Revisions
Managers
NameTitle
Stefan Weber Chief Executive Officer, Director & IR Contact
Ulrich Köstlin Non-Executive Chairman
Roberto Galli Vice President-Finance
Ravi Anand Chief Medical Officer
Patrick J. Langlois Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS SPA-11.55%198
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055